Roche appoints new board members; Sanofi completes €8B refinancing plans; FDA approves new swimmer's ear drug;

@FiercePharma: Top-read special report in pharma Wednesday was our newest, The top 10 patent losses of 2015. Check it out. | Follow @FiercePharma

@EricPFierce: With a 2nd plant on the AstraZeneca chopping block, 430 jobs on two continents now at stake. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: This week in #Vaccines: $GSK shingles candidate hits PhIII mark; Baxter backs out of vaccines. More | Follow @CarlyHFierce

> Roche ($RHHBY) elected Bernard Poussot and Richard Lift to the company's board. Story

> Sanofi ($SNY) finished an €8 billion ($9.8 billion) refinancing of its two syndicated revolving credit facilities. More

> Alcon Labs won FDA approval for Xtoro, a new drug that is used to treat swimmer's ear. Story

> After much industry fanfare, the FDA has proposed a new rule requiring electronic labeling for drug packaging. More

> U.K. cost watchdog NICE recommended AbbVie's ($ABBV) anti-TNF drug Humira for use in adults with moderate to severe ulcerative colitis. Story

> Onyx Pharmaceuticals ($ONXX) gave an all-clear after a suspected gas leak at its South San Francisco facility. More

> Roche won the 2015 Drug Discover of the Year award from the British Pharmacological Society (BPS) for leukemia med Gazyvaro. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Covidien, Stryker tout stroke study that used their stents. Story | Follow @FierceMedDev

@EmilyWFierce: San Francisco startup is reinventing the chicken egg with $90M in tow. Wired story | Follow @EmilyWFierce

> FDA warns against inappropriate use of fetal ultrasound imaging and heartbeat monitoring. News

> AliveCor aims for widespread consumer adoption with new tech, reduced price. Article

> Myriad Genetics stymied in BRCA breast cancer test patent battle. Report

Biotech News

@FierceBiotech: From FierceDrugDelivery: RNAi specialist $ALNY to focus on three therapeutic areas. Article | Follow @FierceBiotech

@JohnCFierce: Merck beefs up its cancer drug pipeline in $375M OncoEthix buyout. News | Follow @JohnCFierce

@DamianFierce: $BLCM opens up 30% at around $24. | Follow @DamianFierce

> Bellicum pulls off a $140M IPO as CAR-T has its day on Wall Street. Article

> Padlock banks $23M with a fresh approach to autoimmune disease. News

> Lundbeck pulls the plug on its fast-tracked stroke drug. Item

> What would an FDA OK on AbbVie's hep C cocktail mean for payers? More

Vaccines News

> Baxter backs away from vaccines with Vero tech sale to Nanotherapeutics. Report

> Study: Universal dengue vaccine may be possible thanks to antibody discovery. More

> Finnish scientists ID link between GSK's swine flu vaccine and narcolepsy. Story

> GSK shingles candidate hits its mark in hefty Phase III study. Article

> China green-lights domestic Ebola shot for clinical trials. Item

Pharma Manufacturing News

> FDA finds issues with Hovione plant in Portugal. Article

> Onyx Pharmaceuticals facility evacuated but no problems found. Item

> Owners, employees of compounder NECC indicted over lethal meningitis outbreak. News

> Pozen gets a second CRL as its API supplier awaits FDA reinspection. Story

> AstraZeneca targets U.K. plant for closure. Report

And Finally… The EU's highest court ruled that obesity can constitute disability if it prevents "full and effective participation" at work. Story

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.